Biologicaltherapy cycles


towards tailored, needs-driven, safer and
cost-effective management of Crohn’s disease.

Europe flag This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633168 – BIOCYCLE (PHC-13-2014).


The objective of the BIOCYCLE project is to assess long-term treatment strategies in Crohn’s disease that will improve both safety and related costs while ensuring a constant level of efficacy during maintenance therapy.

Crohn’s disease is a chronic longstanding disease that can’t be cured with current available treatments. The aim of long-term treatment is to fully control the symptoms and avoid the progression of intestinal damage. Currently, the preferred strategy for moderate-severe disease is a combination therapy with anti-TNFα and anti-metabolites (immunosuppressant). This long-term treatment may lead to cost and safety issues. The BIOCYCLE action will assess the efficacy, safety, effectiveness and feasibility of either anti-TNFα or immunosuppressant withdrawal in those patients.

Project overview

Crohn’s disease

Body inspectation Medecin


Curative therapies do not yet exist and the current best treatments are symptoms relieving therapies. The drug of choice and treatment strategies depend on the clinical characteristics and severity of the disease.

Mild disease may be treated by mesalazine or no treatment with limited number of courses of topical steroids.

The gold standard of care for moderate to severe Crohn’s disease is the Combo therapy, the uninterrupted combination of anti-TNFα monoclonal antibodies and immunosuppressant. However, this kind of treatment raises safety and costs issues.
Indeed, anti-TNFα is the most expensive medication and potential adverse effects are associated with the Combo therapy, namely cancers and possible increase of severe infections. In addition, patients are exposed to class-specific drug complications.

Description of the disease

Doctor inspection Crohn disease

Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) affecting the gastro-intestinal tract. CD often begins at young age and lasts the whole life. The prevalence is 20-30% higher for women than for men.

CD is characterized by a sequence of active disease episodes (flare-ups) and remissions of variable duration. The chronicity of CD has a significant impact on patients’ quality of life (QoL).

Genetic susceptibility, modified composition of the gut microbiota and impaired function of the mucosal immune system are the main known contributors to the etiology of CD. However, the primary cause remains unknown.


The BIOCYCLE project involves a consortium between 13 partners.

Find here all the documents and tools related to this project




The European Project – BIOCYCLE (, project aims at assessing long-term treatment strategies in Crohn’s disease that will improve both safety and related costs while ensuring a constant level of eficacy during maintenance therapy. In that frame, IBDIM (research department of “European Crohn’s disease and Colitis Organization” – ECCO), one of the partners, is recruiting a data manager.

IBDIM role in the project:

WP 2: Dissemination and exploitation of the results

WP 9: Supporting the entry of BIOCYCLE data in the United Registries for […]

view more
News from BIOCYCLE

News from BIOCYCLE

The BIOCYCLE project has now been ongoing for 5 years. This project, funded by the European Commission under the Horizon 2020 programme, aims to explore different aspects of the question of treatment de-escalation in moderate-severe Crohn’s Disease that first requires combination therapy with anti-TNF and antimetabolites to control the disease. Once the disease has been stabilised, an unsolved question is to whether it is possible to de-escalate therapy. This question is important for several reasons, including safety, tolerance, quality of […]

view more